---
title: "NRx Pharma says FDA grants expanded access protocol for NRX-101 depression treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290423993.md"
description: "NRx Pharmaceuticals announced that the FDA has granted clearance for an expanded access protocol for NRX-101. This approval allows the drug to augment accelerated Transcranial Magnetic Stimulation (TMS) in treating treatment-resistant depression. The program provides compassionate-use access to patients who are unable to enroll in the company's pivotal SPARC-TMS trial."
datetime: "2026-06-22T11:00:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290423993.md)
  - [en](https://longbridge.com/en/news/290423993.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290423993.md)
generator: "portal-rs"
---

# NRx Pharma says FDA grants expanded access protocol for NRX-101 depression treatment

-   NRX Pharmaceuticals received FDA clearance for an expanded access protocol for NRX-101 to augment accelerated TMS in treatment-resistant depression. \* The program enables compassionate-use access for patients unable to enroll in the company’s pivotal SPARC-TMS trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220700PRIMZONEFULLFEED9750157) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NRXP.US](https://longbridge.com/en/quote/NRXP.US.md)
- [NRXPW.US](https://longbridge.com/en/quote/NRXPW.US.md)

## Related News & Research

- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)
- [Alumis says Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus misses primary endpoint](https://longbridge.com/en/news/297644348.md)
- [Nextech3D.ai Delivers 101% Revenue Growth in Fiscal Q1 2027 as AI-Powered Event Platform Accelerates](https://longbridge.com/en/news/297511797.md)
- [Pegasystems says Deutsche Kreditbank implements Pega Customer Service for AI-assisted email handling](https://longbridge.com/en/news/297618476.md)
- [Aerowash expands into eco-friendly train and bus washing, sets up new subsidiary](https://longbridge.com/en/news/297483456.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**